FRMI vs MESO Comparison

Fermi Inc develops next-generation private electric grids that deliver redundant power at gigawatt scale to support next-generation intelligence and AI compute. It combines cutting-edge technology with a deep bench of world-class, multidisciplinary leaders with a combined 25 GW of experience to create one of the world's 17 GW next-gen private grids, helping ensure America's energy and AI dominance. The behind-the-meter Project Matador campus is expected to integrate the nation's combined-cycle natural gas project, one of the clean, new nuclear power complexes in America, utility grid power, solar power, and battery energy storage, to support hyperscale AI and computing.

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.